Fernando Rivera
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Otorhinolaryngology top 0.1%
- Head and Neck Cancer Studies
Papers in
- Oncology 148
- Colorectal Cancer Treatments and Studies 118
- Cancer Treatment and Pharmacology 51
- Pancreatic and Hepatic Oncology Research 29
-
- Gastric Cancer Management and Outcomes 50
- Lung Cancer Treatments and Mutations 15
- Co-authors
- Eduardo Díaz‐Rubio (26 shared papers)Arié Figer (7 shared papers)Stephen Clarke (6 shared papers)Leonard B. Saltz (4 shared papers)Florin Sirzén (3 shared papers)Jim Cassidy (3 shared papers)Tsai‐Shen Yang (3 shared papers)Werner Scheithauer (3 shared papers)
- Journals
- Journal of Clinical Oncology (46 papers)Annals of Oncology (29 papers)Clinical & Translational Oncology (14 papers)European Journal of Cancer (8 papers)Clinical Colorectal Cancer (5 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Fernando Rivera
164 papers receiving 12.6k citations
Fernando Rivera's Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 10.2k
- Otorhinolaryngology 1.6k
- Hepatology 2.6k
- Pulmonary and Respiratory Medicine 4.7k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by Fernando Rivera
This map shows the geographic impact of Fernando Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Rivera more than expected).
Fields of papers citing papers by Fernando Rivera
This network shows the impact of papers produced by Fernando Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Rivera. The network helps show where Fernando Rivera may publish in the future.
Co-authors
The 25 scholars most cited alongside Fernando Rivera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Hit paper breakdown → | 2008 | 2594 |
| 2 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Hit paper breakdown → | 2008 | 2275 |
| 3 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1351 |
| 4 | Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 652 |
| 5 | OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Hit paper breakdown → | 2006 | 583 |
| 6 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2022 | 501 |
| 7 | PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer Hit paper breakdown → | 2014 | 478 |
| 8 | 2009 | 423 | |
| 9 | 2012 | 354 | |
| 10 | 2007 | 201 | |
| 11 | 2009 | 189 | |
| 12 | 2020 | 140 | |
| 13 | 2006 | 129 | |
| 14 | 2007 | 103 | |
| 15 | 2009 | 90 | |
| 16 | 2014 | 89 | |
| 17 | 2017 | 79 | |
| 18 | 2009 | 79 | |
| 19 | 2012 | 79 | |
| 20 | 2010 | 78 |
About Fernando Rivera
Fernando Rivera is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Cancer Research and Surgery, having authored 168 papers that have together received 12.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (118 papers), Cancer Treatment and Pharmacology (51 papers), Gastric Cancer Management and Outcomes (50 papers), Genetic factors in colorectal cancer (29 papers), Pancreatic and Hepatic Oncology Research (29 papers), Cancer Genomics and Diagnostics (27 papers), Hepatocellular Carcinoma Treatment and Prognosis (24 papers) and Lung Cancer Treatments and Mutations (15 papers). The work is most often cited by research in Oncology (10.2k citations), Otorhinolaryngology (1.6k citations), Hepatology (2.6k citations), Pulmonary and Respiratory Medicine (4.7k citations) and Pathology and Forensic Medicine (1.9k citations). Fernando Rivera has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Eduardo Díaz‐Rubio, Arié Figer, Stephen Clarke, Leonard B. Saltz, Florin Sirzén, Jim Cassidy, Tsai‐Shen Yang, Werner Scheithauer, Félix Couture and Sheryl Koski. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical & Translational Oncology, European Journal of Cancer and Clinical Colorectal Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.